Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $47.64.

KYMR has been the topic of several research reports. Wells Fargo & Company lifted their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research report on Monday, August 26th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research report on Monday, June 17th. Morgan Stanley boosted their target price on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 14th. Finally, Oppenheimer restated an “outperform” rating and issued a $52.00 price target on shares of Kymera Therapeutics in a report on Wednesday, July 10th.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 16,740 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total value of $593,433.00. Following the transaction, the director now owns 803,792 shares in the company, valued at approximately $28,494,426.40. The sale was disclosed in a filing with the SEC, which is available through this link. In other Kymera Therapeutics news, insider Jared Gollob sold 23,145 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total value of $1,060,272.45. Following the sale, the insider now directly owns 95,470 shares of the company’s stock, valued at $4,373,480.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bruce Booth sold 16,740 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the sale, the director now directly owns 803,792 shares in the company, valued at $28,494,426.40. The disclosure for this sale can be found here. Insiders sold a total of 507,345 shares of company stock worth $19,525,432 over the last three months. 15.82% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. raised its position in Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after acquiring an additional 295 shares in the last quarter. Comerica Bank raised its position in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares during the period. Keudell Morrison Wealth Management boosted its stake in shares of Kymera Therapeutics by 7.2% during the 2nd quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock worth $212,000 after acquiring an additional 480 shares in the last quarter. Congress Asset Management Co. MA grew its position in shares of Kymera Therapeutics by 1.2% during the 1st quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after acquiring an additional 533 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Kymera Therapeutics by 4.7% in the 1st quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock valued at $486,000 after purchasing an additional 547 shares in the last quarter.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $48.36 on Monday. The firm’s 50 day simple moving average is $41.10 and its 200-day simple moving average is $38.41. Kymera Therapeutics has a one year low of $9.60 and a one year high of $50.19. The firm has a market cap of $2.97 billion, a PE ratio of -19.27 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. The business had revenue of $25.60 million during the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. Kymera Therapeutics’s revenue was up 55.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.67) EPS. Equities research analysts predict that Kymera Therapeutics will post -2.86 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.